Tandem autologous hematopoietic cell transplantation with sequential use of total marrow irradiation and high-dose melphalan in multiple myeloma
暂无分享,去创建一个
K. Ślosarek | L. Miszczyk | S. Blamek | B. Jochymek | J. Hołowiecki | G. Woźniak | J. Najda | T. Czerw | M. Saduś-Wojciechowska | S. Giebel | Małgorzata Sobczyk-Kruszelnicka | W. Mendrek | W. Leszczyński | M. Radwan | Ł. Dolla | A. d'Amico | K. Slosarek
[1] K. Michalak,et al. Increased Efficacy of Stem Cell Chemomobilization with Intermediate-Dose Cytarabine Plus Granulocyte Colony-Stimulating Factor (G-CSF) Compared with G-CSF Alone in Patients with Multiple Myeloma: Results of a Randomized Trial. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] N. Geller,et al. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Labopin,et al. Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study. , 2018, International journal of radiation oncology, biology, physics.
[4] P. Hari,et al. Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival , 2018, Bone Marrow Transplantation.
[5] K. Michalak,et al. Reduction of DMSO concentration in cryopreservation mixture from 10% to 7.5% and 5% has no impact on engraftment after autologous peripheral blood stem cell transplantation: results of a prospective, randomized study , 2018, Bone Marrow Transplantation.
[6] U. Mellqvist,et al. Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study , 2017 .
[7] W. Wiktor-Jedrzejczak,et al. Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party , 2017, Haematologica.
[8] M. Loh,et al. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. , 2017, Blood.
[9] S. Parmar,et al. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. , 2017, The Lancet. Haematology.
[10] N. Munshi,et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.
[11] Scott E. Smith,et al. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] S. Molica,et al. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy , 2016, Bone Marrow Transplantation.
[13] W. Kremers,et al. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] M. Boccadoro,et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.
[15] M. Boccadoro,et al. Autologous transplantation and maintenance therapy in multiple myeloma. , 2014, The New England journal of medicine.
[16] K. Ślosarek,et al. Method of total marrow irradiation (TMI) , 2014 .
[17] A. Tukiendorf,et al. A faster reconstitution of hematopoiesis after autologous transplantation of hematopoietic cells cryopreserved in 7.5% dimethyl sulfoxide if compared to 10% dimethyl sulfoxide containing medium. , 2013, Cryobiology.
[18] E. Chmielowska,et al. Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers , 2013, Bone Marrow Transplantation.
[19] C. Solano,et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] A. Krishnan,et al. Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma , 2010, Clinical Cancer Research.
[21] L. Escoda,et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study , 2010, Haematologica.
[22] M. Boccadoro,et al. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. , 2010, Blood.
[23] An Liu,et al. Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. , 2009, International journal of radiation oncology, biology, physics.
[24] M. Baccarani,et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[26] An Liu,et al. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[27] Susanta K Hui,et al. Feasibility study of helical tomotherapy for total body or total marrow irradiationa). , 2005, Medical physics.
[28] J. Fowler,et al. Feasibility study of helical tomotherapy for total body or total marrow irradiation. , 2005, Medical physics.
[29] R. Bataille,et al. Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.
[30] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[31] J. Rossi,et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.